Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).

6044 Background: Preclinical data suggest that simultaneous inhibition of PI3K and EGFR leads to synergistic antitumor activity in SCCHN. BYL719 is a potent, oral inhibitor of the α-isoform of clas...